 Fluorouracil
"Fluorouracil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
| Descriptor ID |
D005472
|
| MeSH Number(s) |
D03.383.742.698.875.404
|
| Concept/Terms |
Fluorouracil- Fluorouracil
- 5FU
- 5-FU
- 5-Fluorouracil
- 5 Fluorouracil
- Fluoruracil
Efudix- Efudix
- Fluoro-Uracile ICN
- Fluoro Uracile ICN
- Efudex
|
Below are MeSH descriptors whose meaning is more general than "Fluorouracil".
Below are MeSH descriptors whose meaning is more specific than "Fluorouracil".
This graph shows the total number of publications written about "Fluorouracil" by people in this website by year, and whether "Fluorouracil" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 1 | 2 | | 1998 | 0 | 2 | 2 | | 1999 | 2 | 2 | 4 | | 2000 | 0 | 2 | 2 | | 2001 | 1 | 2 | 3 | | 2002 | 1 | 2 | 3 | | 2003 | 2 | 0 | 2 | | 2004 | 0 | 4 | 4 | | 2005 | 0 | 1 | 1 | | 2006 | 1 | 4 | 5 | | 2007 | 0 | 2 | 2 | | 2008 | 3 | 4 | 7 | | 2009 | 0 | 3 | 3 | | 2010 | 3 | 5 | 8 | | 2011 | 0 | 1 | 1 | | 2012 | 0 | 3 | 3 | | 2013 | 1 | 9 | 10 | | 2014 | 0 | 3 | 3 | | 2015 | 0 | 1 | 1 | | 2016 | 3 | 8 | 11 | | 2017 | 1 | 5 | 6 | | 2018 | 3 | 0 | 3 | | 2019 | 2 | 7 | 9 | | 2020 | 1 | 2 | 3 | | 2021 | 1 | 9 | 10 | | 2022 | 1 | 7 | 8 | | 2023 | 1 | 1 | 2 | | 2024 | 1 | 9 | 10 | | 2025 | 1 | 10 | 11 | | 2026 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Fluorouracil" by people in Profiles.
-
Peng C, Catalano P, Zalcberg J, Thor AD, Weiner LM, Khandekar JD, Cohen D, Weinshel EL, O'Dwyer PJ, Benson AB. ECOG-ACRIN E6293: Phase II Study of Raltitrexed in Advanced Colorectal Cancer. Oncologist. 2026 Apr 10; 31(5).
-
Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O'Reilly EM, Meyerhardt JA. Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26; 394(12):1155-1166.
-
El Rouby N, Aquilante CL, Bargal SA, Cavallari LH, Duarte JD, Gunderson K, Mazhindu T, Nagy M, Nie X, Nguyen DG, Patel JN, Skaar TC, Smith DM, Tuteja S, van Schaik RHN, Hicks JK. Global Investigation of Clinical Implementation Strategies for DPYD Testing to Guide Fluoropyrimidine Therapy. Clin Transl Sci. 2026 Jan; 19(1):e70466.
-
Ito R, Oba A, Kobayashi T, Sugita K, Takamatsu M, Fukuoka S, Shinozaki E, Tsuchiya S, Matsueda K, Kobayashi K, Ono Y, Ito H, Inoue Y, Saiura A, Takahashi Y. Managing dual primary liver metastases from breast and colorectal cancers. Clin J Gastroenterol. 2026 Feb; 19(1):91-99.
-
Lentz RW, Hu J, Robinson H, Balmaceda N, Baiyee E, Leal AD, Kim SS, Davis SL, Messersmith WA, Lieu CH. Real-World Analysis of Irinotecan With or Without Fluorouracil in the Second-Line Treatment of Metastatic Colorectal Cancer. J Natl Compr Canc Netw. 2025 Aug; 23(8).
-
Omiya K, Oba A, Sugiura K, Maekawa A, Mie T, Kobayashi K, Ono Y, Sasaki T, Ozaka M, Sasahira N, Ito H, Inoue Y, Takahashi Y. Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy. Ann Surg Oncol. 2025 Aug; 32(8):5411-5420.
-
Stoop TF, Wu YHA, Oba A, Ali M, Feld IM, Al-Musawi MH, Jain A, Saiura A, Sauvanet A, Coppola A, Javed AA, Groot Koerkamp B, Miller BN, Hashimoto D, Caputo D, Kleive D, Sereni E, Kazemier G, Belfiori G, Ishida H, van Dam JL, Dembinski J, Akahoshi K, Roberts KJ, Tanaka K, Labori KJ, Falconi M, House MG, Sugimoto M, Tanabe M, Gotohda N, Chatzizacharias N, Krohn PS, Dokmak S, Rodriguez Franco S, Hirano S, Burgdorf SK, Crippa S, Satoi S, Nguyen TK, Yamamoto T, Nakamura T, Ushida Y, Bachu V, Burns WR, Inoue Y, Takahashi Y, Aslami Z, Schulick RD, He J, Messersmith W, Besselink MG, Burkhart RA, Wilmink JW, Del Chiaro M. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an international multicentre study. Br J Cancer. 2025 Jul; 133(1):76-84.
-
Yamashita T, Fujimasa K, Otsuka K, Saito A, Kohmoto M, Motegi K, Ariyoshi T, Goto S, Yamochi T, Takimoto M, Hirasawa Y, Kubota Y, Yoshimura K, Tsunoda T, Murakami M, Aoki T. Efficacy of Esophagectomy Following Neoadjuvant Chemotherapy for Esophageal Neuroendocrine Carcinoma. Anticancer Res. 2025 May; 45(5):2051-2058.
-
Ono Y, Ito R, Kobayashi K, Oba A, Sato T, Ito H, Inoue Y, Takahashi Y. Technique of Circumferential Divestment of the Superior Mesenteric Artery for Locally Advanced Pancreatic Cancer. Ann Surg Oncol. 2025 Jun; 32(6):4417-4418.
-
Stoop TF, Sugawara T, Oba A, Feld IM, van Roessel S, van Veldhuisen E, Wu YHA, Nishino J, Ali M, Alseidi A, Sauvanet A, Mirabella A, Sa Cunha A, Kokkola A, Groot Koerkamp B, Pietrasz D, Kleive D, Butturini G, Malleo G, van Laarhoven HWM, Frigerio I, Dembinski J, He J, Gagnière J, Kleeff J, Ramia JM, Roberts KJ, Labori KJ, Marino MV, Falconi M, B Mortensen M, Lesurtel M, Bonds M, Chatzizacharias N, Strobel O, Turrini O, Griffin O, Franklin O, Pfeiffer P, Schulick RD, Salvia R, de Wilde RF, Dokmak S, Rodriguez Franco S, Augustinus S, Burgdorf SK, Crippa S, Hackert T, Tarvainen T, Burns WR, Messersmith W, Wilmink JW, Burkhart RA, Del Chiaro M, Besselink MG. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. JAMA Oncol. 2025 Mar 01; 11(3):276-287.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|